Nyrada Successfully Completes Safety Studies Ahead of Phase I Clinical Trial
Nyrada Inc (ASX:NYR) has announced the successful completion of their Good Laboratory Practice (GLP) safety studies on its lead drug… Read more
Nyrada Inc (ASX:NYR) has announced the successful completion of their Good Laboratory Practice (GLP) safety studies on its lead drug… Read more
Highlights: • In vivo micronucleus study completed providing further data to support safety of Nyrada’s lead Brain Injury drug candidate… Read more
On Tuesday morning, Nyrada Inc. (ASX: NYR) released a significant announcement about a potential new indication for its lead drug… Read more
Nyrada Inc (ASX: NYR) have released an announcement updating the market on the Good Laboratory Practice (GLP) studies. The latest… Read more
› Drug discovery and development company specialising in rational design of novel small molecule therapeutics. › Nyrada’s lead drug candidate… Read more
Highlights: •Completed dog cardiovascular study provides ongoing data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate… Read more
“Our lead brain injury program candidate, NYR-BI03, is targeting a very large and growing market. There are no current FDA-approved… Read more
Highlights: •Completed rat respiratory study provides additional data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate…. Read more
Improving Lives, Offering Hope